Kurma, Sunstone lead CHF 20m round for Synendos Therapeutics

Also participating in the round were Bernina Bioinvest, Schroder Adveq, High-Tech Gründerfonds (HTGF), Lichtsteiner Foundation, Essential Investments and Zürcher Kantonalbank.

The company plans to use the capital to complete pre-clinical development of its therapy and to conduct a proof-of-concept clinical study.

Following the round, Peter Neubeck of Kurma Partners, Søren Lemonius of Sunstone Life Science Ventures and Bettina Ernst of Bernina Bioinvest will join Synendos's management board.

Previous funding
Between December 2018 and November 2019, Synendos received total funding of CHF 260,000 from Switzerland-based initiative Venture Kick.

Company
Synendos Therapeutics is developing a small molecule-based therapy that it claims can be used in the treatment of central nervous system (CNS) disorders, focusing on the brain's endocannabinoid system. The company was founded in 2019 as a spinout of the University of Bern and the NCCR TransCure research consortium.

People
Synendos Therapeutics – Andrea Chicca (CEO).
Sunstone Life Science Ventures – Søren Lemonius (managing partner).
Kurma Partners – Peter Neubeck (partner).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Venture
• Germany
• High-Tech Gründerfonds
• Schroder Adveq